YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7301-7312

  Pikor, Larissa A ^a   Lockwood, William W ^b   Thu, Kelsie L ^a   Vucic, Emily A ^a   Chari, Raj ^c   Gazdar, Adi F ^d   Lam, Stephen ^a   Lam, Wan L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BRONCHUS MUCOSA; CANCER RESISTANCE; CELL AGING; CELL PROLIFERATION; CHROMOSOME 12Q; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; EPITHELIUM CELL; GENE AMPLIFICATION; GENE DOSAGE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RNA INTERFERENCE; TUMOR GROWTH; YEATS4 GENE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEIC ACID HYBRIDIZATION; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891277461     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1897     Document Type: Article

References (49)

1. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
2. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
3. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
4. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
5. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-51.
6. Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, Lam S, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 2008;27:4615-24.
7. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8.
8. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-42.
9. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002; 86:1449-56.
10. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007;57:664-71.
11. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation ofMETby gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009;4:5-11.
12. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
13. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21.
14. Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 2012;7:e37775.
15. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 2010;102:1310-21.
16. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36:299-303.
17. Khojasteh M, Lam WL, Ward RK, MacAulay C. A stepwise framework for the normalization of array CGH data. BMC Bioinform 2005;6:274.
18. Jong K, Marchiori E, Meijer G, Vaart AV, Ylstra B. Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics 2004;20:3636-7.
19. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
21. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 2010;7: E1000315.
22. Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL, et al. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clin Cancer Res 2012;18: 1936-46.
23. Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, et al. Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kB pathway activation in lung cancer. J Thorac Oncol 2011;6:1521-9.
24. Coe BP, Chari R, MacAulay C, Lam WL. FACADE: A fast and sensitive algorithm for the segmentation and calling of high resolution arrayCGH data. Nucleic Acids Res 2010;38:e157.
25. Chari R, Lonergan KM, Pikor LA, Coe BP, Zhu CQ, Chan TH, et al. A sequence-based approach to identify reference genes for gene expression analysis. BMC Med Genom 2010;3:32.
26. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005;65:5561-70.
27. Job B, Bernheim A, Beau-Faller M, Camilleri-Broet S, Girard P, Hofman P, et al. Genomic aberrations in lung adenocarcinoma in never smokers. PLoS One 2010;5:e15145.
28. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
29. Fischer U, Heckel D, Michel A, Janka M, Hulsebos T, Meese E. Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade I. Hum Mol Genet 1997;6:1817-22.
30. Munnia A, Schutz N, Romeike BF, Maldener E, Glass B, Maas R, et al. Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor. Oncogene 2001;20:4853-63.
31. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715-21.
32. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008; 14:822-7.
33. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
34. Park JH, Roeder RG. GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol Cell Biol 2006;26:4006-16.
35. Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol 2009;11:257-68.
36. Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, et al. Identification of transcription factors associated with castration- resistance: Is the serum responsive factor a potential therapeutic target Prostate 2013;73:743-53.
37. Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, et al. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 2010;29:73-93.
38. Zimmermann K, Ahrens K, Matthes S, Buerstedde JM, Stratling WH, Phi-van L. Targeted disruption of the GAS41 gene encoding a putative transcription factor indicates that GAS41 is essential for cell viability. J Biol Chem 2002;277:18626-31.
39. Schulze JM, Wang AY, Kobor MS. YEATS domain proteins: A diverse family with many links to chromatin modification and transcription. Biochem Cell Biol 2009;87:65-75.
40. Cai Y, Jin J, Florens L, Swanson SK, Kusch T, Li B, et al. The mammalian YL1 protein is a shared subunit of the TRRAP/TIP60 histone acetyltransferase and SRCAP complexes. J Biol Chem 2005;280:13665-70.
41. Doyon Y, Selleck W, Lane WS, Tan S, Cote J. Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol Cell Biol 2004;24:1884-96.
42. Piccinni E, Chelstowska A, Hanus J, Widlak P, Loreti S, Tata AM, et al. Direct interaction of Gas41 and Myc encoded by amplified genes in nervous system tumours. Acta Biochim Pol 2011;58:529-34.
43. Lauffart B, Howell SJ, Tasch JE, Cowell JK, Still IH. Interaction of the transforming acidic coiled-coil 1 (TACC1) protein with ch-TOG and GAS41/NuBI1 suggests multiple TACC1-containing protein complexes in human cells. Biochem J 2002;363:195-200.
44. Harborth J,Weber K, Osborn M. GAS41, a highly conserved protein in eukaryotic nuclei, binds to NuMA. J Biol Chem 2000;275: 31979-85.
45. Debernardi S, Bassini A, Jones LK, Chaplin T, Linder B, de Bruijn DR, et al. The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex. Blood 2002;99:275-81.
46. Schmitt J, Fischer U, Heisel S, Strickfaden H, Backes C, Ruggieri A, et al. GAS41 amplification results in overexpression of a new spindle pole protein. Genes Chromosomes Cancer 2012;51:868-80.
47. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: P53 and beyond. Cell Death Differ 2010;17:93-102.
48. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010;24:1580-9.
49. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.